Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7838746 | 0.84 | MTNR1A (0.61) | GRIN2BCA1CA2SIGMAR1MTNR1A | |
| Bromide SCHEMBL7336860 | 0.83 | MTNR1A (0.59) | GRIN2BCA1CA2SIGMAR1MTNR1A | |
| SCHEMBL11145258 | 0.81 | CDK8 (0.46) | GRIN2BIDO1CA1CA2SIGMAR1 | |
| SCHEMBL13846495 | 0.78 | GRIN2B (0.55) | GRIN2BIDO1CA1CA2SIGMAR1 | |
| SCHEMBL6589968 | 0.78 | CA1 (0.52) | GRIN2BIDO1CA1CA2SIGMAR1 | |
| SCHEMBL6199794 | 0.75 | GRIN2B (0.52) | GRIN2BCA1CA2SIGMAR1MTNR1A | |
| SCHEMBL11067202 | 0.75 | TP53 (0.49) | MAPT | |
| SCHEMBL714537 | 0.74 | SIGMAR1 (0.53) | GRIN2BIDO1CA1CA2SIGMAR1 | |
| SCHEMBL6904134 | 0.74 | CA1 (0.54) | GRIN2BIDO1CA1CA2SIGMAR1 | |
| SCHEMBL1488586 | 0.74 | CA1 (0.48) | GRIN2BIDO1CA1CA2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| WO-2007015775-A2 | POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
| US-5763631-A | CIS-EPOXIDE COMPOUNDS; ANTIVIRUS AGENTS; USEFUL TO TREAT THE AIDS | LUCKY LIMITED (KR) | 1998-06-09 | — | — | US | disclosed |
| US-5744621-A | CIS-EPOXIDE COMPOUNDS | LUCKY LIMITED. (KR) | 1998-04-28 | — | — | US | disclosed |
| EP-0601486-B1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD (KR) | 1997-10-29 | — | — | EP | disclosed |
| US-5587388-A | AIDS; VIRICIDES | LUCKY LIMITED (KR) | 1996-12-24 | — | — | US | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
| EP-0144235-A2 | N6-(1- and 2-benzocycloalkyl) adenosines, pharmaceutical compositions comprising the same and a process for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | GRIN2B 2224/4885IDO1 115/4885CA1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.